Last reviewed · How we verify
ABM-1310
ABM-1310 is an experimental cancer drug tested in early trials for advanced tumors and BRAF-mutant cancers.
ABM-1310 is an investigational targeted therapy evaluated in Phase 1 trials for advanced solid tumors and BRAF V600-mutant cancers. It is being studied for its safety and tolerability in small patient cohorts, with no approved indications yet.
At a glance
| Generic name | ABM-1310 |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
ABM-1310 is an investigational drug currently being studied in early-stage clinical trials. It is being tested in patients with advanced solid tumors and those with BRAF V600-mutant cancers, including cases that have relapsed or become resistant to other treatments. The drug is in the Phase 1 stage, which means researchers are primarily focused on understanding its safety and how well it is tolerated by patients. At this point, it is not approved for any specific use and is still under evaluation.
Approved indications
Common side effects
Key clinical trials
- A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics &Preliminary Anti-Cancer Efficacy of ABM-1310 in Patients With BRAF V600-Mutant Relapsed &Drug (Phase 1)
- A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Cancer Activity of ABM-1310 in Patients With BRAF V (Phase 1)
- A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABM-1310 CI brief — competitive landscape report
- ABM-1310 updates RSS · CI watch RSS
- portfolio CI